Publications

430P CLDN18. 2 and KRAS signaling shape tumor states and immune microenvironment in pancreatic cancer (PC)

V Nasca, M Hilmi, N Tezcan, M Perry, M May, J Song, F Balogun, ...

Abstract A042: ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort

J Guo, M May, MF Berger, E Cismas, M Hilmi, A Singhal, F Balogun, ...

Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report

Kouassi FM, Patel H, Karnoub ER, Tsang CF, Hohenleitner J, Basturk O, Budagavi D, Moza M, et al.

Dual pancreatic carcinomas: clonally related or independent primaries?

Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, et al.

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial

Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, Varghese AM, White C, et al.

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

M Hilmi, JD Schoenfeld, W McKerrow, Y Elhanati, CA O'Connor, S Umeda, ...

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

W Park, CA O’Connor, JF Chou, M Hilmi, Z Tarcan, C Schwartz, M Larsen, ...

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

2223P First-line (1L) AZD0171+ durvalumab (D)+ chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results

S Chandana, A Ruiz-Casado, RA Gallego, AL Coveler, R El-Maraghi, ...

Abstract A097: Impact of socioeconomic status on survival outcomes in patients with stage IV pancreatic adenocarcinoma: A race/ethnicity controlled analysis

A Erakky, S Nandakumar, M Waters, J Duque-Jimenez, A Awuah, M Lao, ...

Abstract B044: Black and Hispanic patients with pancreatic ductal adenocarcinoma (PDAC) have worse overall survival than Asian and White patients with PDAC, despite having more …

JB Duque-Jimenez, AN Awuah, A Erakky, S Nandakumar, M Waters, ...

Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

CA O'Connor, JW Lee, E Harrold, AL Richards, D Muldoon, ...

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.

JW Lee, CA O'Connor, E Harrold, AL Richards, F Velez-Cortes, D Moss, ...

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Fecal Immunochemical Tests (FIT) and Focus Groups: Tailoring Bilingual Cancer Screening Education

Haveric A, Balogun F, Gilliland J, Narang B, Gany F

Metastatic Epstein-Barr Virus-Associated Lymphoepithelioma-Like Carcinoma of Small Bowel Origin

JJ Tao, H Hibshoosh, SM Lagana, F Balogun, RA White

Molecular differences in pancreatic ductal adenocarcinomas from black versus white patients

S Mandal, EA Teslow, M Huang, Y Yu, S Sridhar, HC Crawford, ...

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Toward Early Detection: A Scoping Review of Hepatocellular Cancer Surveillance in Sub-Saharan Africa

S Okeke, O Adewara, D Akoki, I Ijezie, M Abraham, D Irabor, F Balogun

1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination …

W Park, C O’Connor, J Chou, C Schwartz, M Larsen, A Varghese, K Yu, ...

Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ...

Abstract C104: Dual primary pancreas cancers–Related or independent lesions?

JD Schoenfeld, H Sahan-Ozkan, N Bilani, MI D'Angelica, WR Jarnagin, ...

Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes.

F Keane, D Moss, CA O'Connor, M Perry, JF Chou, F Crowley, P Saxena, ...

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, et al.

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.

Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.

CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ...

Tumor progression and tumor microenvironment of pancreas cancer ascites revealed by scRNA-seq and spatial transcriptomics

S Umeda, ER Karnoub, F Balogun, A Jiménez-Sánchez, ...

A single cell landscape of malignant pancreas cancer ascites

S Umeda, ER Karnoub, E Ziv, J Wu, C Cruz, W Park, F Balogun, ...

Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).

F Keane, F Balogun, C O'Connor, F Crowley, A Chan, D Cowzer, JF Chou, ...

Africa Guidelines for Hepatocellular Carcinoma Buildup Process

Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, et al.

Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).

F Keane, L Saadat, C O'Connor, JF Chou, AR Brannon, D Cowzer, ...

Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with …

F Balogun, M Altoe, C O'Connor, N Chowdhury, A Cercek, C Lee, ...

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination …

W Park, C O'Connor, JF Chou, C Schwartz, AM Varghese, M Larsen, ...

The Onc Docs: Partnering with Black cancer patients for cancer education.

F Balogun, O Balogun

1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer

F Keane, W Park, A Varghese, F Balogun, K Yu, I El Dika, D Khalil, ...

Abstract CT126: a phase 2 trial of first-line AZD0171+ durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell …

G O'Kane, T Macarulla, F Balogun, A Hollebecque, MJ Reilley, ...

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?

F Balogun, D Raben

Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with …

MR Weiser, JF Chou, A Keshinro, WC Chapman Jr, PS Bauer, MG Mutch, ...

Oral squamous cell carcinoma as a complication of treatment for recurrent high‐grade serous cancer

LE Moses, JM Rotsides, FO Balogun, MS Persky, FM Muggia, MJ Persky

Abstract I14: Polymerase theta synthetic lethal interaction in homologous recombination-deficient pancreatic ductal adenocarcinoma

A Wang, A Zamperone, M Sohail, L Wang, F Balogun, J Li, E Zhao, ...

Massive enoxaparin overdose partially reversed with low doses of protamine

J de Olano, F Balogun, C Waslsh, C Ramprasad, D Green, M Miller, ...

ISOLATED THROMBOCYTOSIS AND A MASS IN THE HEART

M Rufin, F Balogun, D Randlett

DNA resection proteins Sgs1 and Exo1 are required for G1 checkpoint activation in budding yeast

FO Balogun, AW Truman, SJ Kron

DNA Resection and Chromatin Remodeling in G1 Checkpoint Activation of Budding Yeast

FO Balogun

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations

CL Liquori, MJ Berg, AM Siegel, E Huang, JS Zawistowski, TP Stoffer, ...